Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00162305 · ClinicalTrials.gov registry record · Phase 2
A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT00162305 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 47 participants.
The verdict
NCT00162305, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to assess the safety of, exposure to, and biological effects of BMS-512148 in stable Type 2 diabetic subjects
Interventions
- DRUG Placebo
- DRUG BMS-512148
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2005-04 |
| Est. Completion | 2005-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00162305
The ClinicalTrials.gov registry entry for NCT00162305 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00162305 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00162305 about?
NCT00162305 is a clinical study titled "A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects". The purpose of this clinical research study is to assess the safety of, exposure to, and biological effects of BMS-512148 in stable Type 2 diabetic subjects
What is the current status of trial NCT00162305?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2005-04. Estimated completion is 2005-08.
What interventions are being tested in trial NCT00162305?
The interventions under investigation include: Placebo (DRUG), BMS-512148 (DRUG).
Who is sponsoring clinical trial NCT00162305?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.